文献速递脊柱关节炎

艾佐奇贝治疗活动性银屑病关节炎的疗效与安全性:一项随机双盲安慰剂对照2期研究

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
PubMed 文献 · Ann Rheum Dis · 2025-04-11

这项2期多中心安慰剂对照研究将135例活动性银屑病关节炎患者按1:1:1随机分配至艾佐奇贝40 mg、80 mg或安慰剂组,每2周给药一次共16周,随后安慰剂组转为艾佐奇贝80 mg。第16周艾佐奇贝80 mg组ACR50应答率显著高于安慰剂组(52% vs 13%,双侧P=0.0006)。艾佐奇贝在多个疾病领域较安慰剂有显著且有临床意义的改善,80 mg组应答率持续增至第46周,未发现意外安全风险。

要点

  • 第16周ACR50应答率艾佐奇贝80 mg组52% vs 安慰剂组13%(双侧P=0.0006)。
  • 第12周ACR50应答率艾佐奇贝80 mg组50% vs 安慰剂组6%(P<0.0001)。
  • 艾佐奇贝80 mg组应答率至第46周总体持续增加,未发现意外安全风险。

核心结论

  • 艾佐奇贝在多个疾病领域较安慰剂产生显著且有临床意义的改善,原随机分配的80 mg剂量至第46周显示持续改善。
  • 未发现意外安全风险;艾佐奇贝分子小且效力高,有潜力进一步改善疾病控制,支持对更高剂量开展进一步研究。

研究设计与样本

  • 2期、多中心、安慰剂对照研究,将活动性银屑病关节炎成人患者按1:1:1随机分配至艾佐奇贝40 mg、艾佐奇贝80 mg或安慰剂,每2周给药一次共16周,随后安慰剂组患者转为艾佐奇贝80 mg。
  • 主要终点为第16周艾佐奇贝80 mg组 vs 安慰剂组的美国风湿病学会50(ACR50)应答;其他疗效终点和治疗中出现的不良事件评估至第16周(安慰剂对照)和第46周。
  • 筛查172例患者,135例被随机分配至艾佐奇贝40 mg组(n=44)、艾佐奇贝80 mg组(n=47)或安慰剂组(n=44)。

主要发现

  • 第16周ACR50应答率艾佐奇贝80 mg组52% vs 安慰剂组13%(双侧P=0.0006);第12周艾佐奇贝80 mg组50% vs 安慰剂组6%(P<0.0001)。
  • 艾佐奇贝40 mg组第16周和第12周ACR50应答率分别为48%和43%,低于艾佐奇贝80 mg组的相应应答率。
  • 对关节炎、银屑病、附着点炎、指趾炎和生活质量结局的额外分析支持两种剂量艾佐奇贝的疗效。
  • 艾佐奇贝80 mg组应答率至第46周总体持续增加。
  • 除注射部位反应外,各治疗组治疗中出现的不良事件发生率总体相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks. METHODS: This phase 2, multicentre, placebo-controlled study randomised adult patients with active PsA 1:1:1 to izokibep 40 mg, izokibep 80 mg, or placebo every 2 weeks for 16 weeks; subsequently, placebo-treated patients switched to izokibep 80 mg. The primary end point was American College of Rheumatology criteria 50 (ACR50) at week 16 for izokibep 80 mg vs placebo. Additional efficacy end points and treatment-emergent adverse events were evaluated through week 16 (placebo-controlled) and week 46. RESULTS: Of 172 patients screened, 135 were randomised to izokibep 40 mg (n = 44), izokibep 80 mg (n = 47), or placebo (n = 44). ACR50 response rates were significantly higher for izokibep 80 mg vs placebo at week 16 (52% vs 13%; 2-sided P = .0006) and week 12 (50% vs 6%; P < .0001); lower rates were observed for izokibep 40 mg (48% and 43% for weeks 16 and 12, respectively). Additional analyses of arthritis, psoriasis, enthesitis, dactylitis, and quality of life outcomes supported the efficacy of izokibep at both doses. Response rates generally continued to increase through week 46 with izokibep 80 mg. Treatment-emergent adverse event rates were generally similar across treatment groups except for injection site reactions. CONCLUSIONS: Izokibep resulted in significant and clinically meaningful improvements over placebo across multiple disease domains, and the originally randomised 80-mg dose showed continued improvements to week 46. There were no unexpected safety risks identified. Izokibep's small size and high potency have the potential for further improved disease control, justifying additional investigation of higher doses.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Mease PJ, de Vlam K, et al. Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Ann Rheum Dis. 2025. PMID: 40455082. doi:10.1016/j.ard.2025.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。